World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
108
Citations
45059
World Ranking
5983
National Ranking
169

Rodney J. Hicks publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Rodney J. Hicks sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 856 publications — 90th percentile

90% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Rodney J. Hicks D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Rodney J. Hicks sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 108 D-Index — 71st percentile

71% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Rodney J. Hicks is affiliated with the Peter MacCallum Cancer Centre in Australia. Their research output is predominantly focused within the field of Medicine, with a considerable concentration on Oncology and Radiology, Nuclear Medicine and Imaging. Subfields including Pulmonary and Respiratory Medicine, Epidemiology, and Neurology also contribute to their body of work.

Their publication record spans a variety of topics that include:

  • Neuroendocrine Tumor Research Advances
  • Neuroblastoma Research and Treatments
  • Radiopharmaceutical Chemistry and Applications
  • Lung Cancer Research Studies
  • Medical Imaging Techniques and Applications
  • Radiomics and Machine Learning in Medical Imaging
  • Cancer Immunotherapy and Biomarkers

Rodney J. Hicks has published extensively in several frequent venues, indicating a focus on nuclear medicine and oncology-related journals. These publication venues include:

  • Journal of Nuclear Medicine
  • European Journal of Nuclear Medicine and Molecular Imaging
  • Cancer Imaging
  • Journal of Clinical Oncology
  • Nature Communications

Their recent papers feature topics covering molecular imaging, PET-CT applications in cancer, biomarker analyses, and procedural guidelines in radioligand therapy. Key recent publications are:

  • Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study, 2020, The Lancet
  • PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial, 2022, The Lancet Oncology
  • Consensus on molecular imaging and theranostics in neuroendocrine neoplasms, 2021, European Journal of Cancer
  • Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT), 2023, European Journal of Nuclear Medicine and Molecular Imaging
  • International consensus on initial screening and follow-up of asymptomatic SDHx mutation carriers, 2021, Nature Reviews Endocrinology

Co-authorship has been a notable element of their research, with frequent collaboration with several researchers. Their top co-authors include:

  • Amir Iravani
  • Michael S. Hofman
  • Jason Callahan
  • Grace Kong
  • Shahneen Sandhu

Best Publications

  • Use of Positron Emission Tomography for Response Assessment of Lymphoma: Consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma

    Malik E. Juweid;Sigrid Stroobants;Otto S. Hoekstra;Felix M. Mottaghy

  • Role of Imaging in the Staging and Response Assessment of Lymphoma: Consensus of the International Conference on Malignant Lymphomas Imaging Working Group

    Sally F. Barrington;N. George Mikhaeel;Lale Kostakoglu;Michel Meignan

  • Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study

    Michael S. Hofman;Michael S. Hofman;Nathan Lawrentschuk;Roslyn J. Francis;Roslyn J. Francis;Colin Tang

  • [177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study.

    Michael S Hofman;Michael S Hofman;John Violet;Rodney J Hicks;Rodney J Hicks;Justin Ferdinandus

  • Delivering affordable cancer care in high-income countries

    Richard Sullivan;Jeffrey Peppercorn;Karol Sikora;John Zalcberg

  • Prognostic Significance of [18F]-Misonidazole Positron Emission Tomography–Detected Tumor Hypoxia in Patients With Advanced Head and Neck Cancer Randomly Assigned to Chemoradiation With or Without Tirapazamine: A Substudy of Trans-Tasman Radiation Oncology Group Study 98.02

    Danny Rischin;Rodney J. Hicks;Richard Fisher;David Binns

  • Positron Emission Tomography Is Superior to Computed Tomography Scanning for Response-Assessment After Radical Radiotherapy or Chemoradiotherapy in Patients With Non–Small-Cell Lung Cancer

    Michael P. Mac Manus;Rodney J. Hicks;Jane P. Matthews;Allan McKenzie

  • Evaluation of Circulating Tumor Cells and Circulating Tumor DNA in Non–Small Cell Lung Cancer: Association with Clinical Endpoints in a Phase II Clinical Trial of Pertuzumab and Erlotinib

    Elizabeth A. Punnoose;Siminder Atwal;Weiqun Liu;Rajiv Raja

  • Somatostatin Receptor Imaging with 68Ga DOTATATE PET/CT: Clinical Utility, Normal Patterns, Pearls, and Pitfalls in Interpretation

    Michael S. Hofman;W. F. Eddie Lau;Rodney J. Hicks

  • ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: peptide receptor radionuclide therapy with radiolabeled somatostatin analogs.

    Rodney J Hicks;Dik J Kwekkeboom;Eric Krenning;Lisa Bodei

  • MRI-negative PET-positive temporal lobe epilepsy: a distinct surgically remediable syndrome.

    R. P. Carne;T. J. O'Brien;T. J. O'Brien;C. J. Kilpatrick;C. J. Kilpatrick;L. R. MacGregor;L. R. MacGregor

  • Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma

    Constantine S Tam;Mary Ann Anderson;Christiane Pott;Rishu Agarwal

  • ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Radiological, Nuclear Medicine and Hybrid Imaging

    Anders Sundin;Rudolf Arnold;Eric Baudin;Jaroslaw Cwikla

  • 90Y-Edotreotide for Metastatic Carcinoid Refractory to Octreotide

    David L. Bushnell;Thomas M. O'Dorisio;M. Sue O'Dorisio;Yusuf Menda

  • Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing

    David M. Kurtz;Michael R. Green;Scott V. Bratman;Florian Scherer

  • Dosimetry of 177Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: Correlations Between Pretherapeutic Imaging and Whole-Body Tumor Dosimetry with Treatment Outcomes.

    John A Violet;Price Jackson;Justin Ferdinandus;Shahneen Sandhu

  • High rate of detection of unsuspected distant metastases by pet in apparent stage III non-small-cell lung cancer: implications for radical radiation therapy.

    Michael P Mac Manus;Rodney J Hicks;Jane P Matthews;Annette Hogg

  • Prostate-specific Membrane Antigen PET: Clinical Utility in Prostate Cancer, Normal Patterns, Pearls, and Pitfalls

    Michael S Hofman;Rodney J Hicks;Tobias Maurer;Matthias Eiber

  • EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands (177Lu-PSMA-RLT).

    Clemens Kratochwil;Wolfgang Peter Fendler;Matthias Eiber;Richard Baum

  • UV-associated mutations underlie the etiology of MCV-negative Merkel cell carcinomas

    Stephen Q. Wong;Kelly Waldeck;Ismael A. Vergara;Jan Schröder;Jan Schröder;Jan Schröder

Frequent Co-Authors

Michael S. Hofman
Michael S. Hofman Peter MacCallum Cancer Centre
Carleen Cullinane
Carleen Cullinane Peter MacCallum Cancer Centre
Grant A. McArthur
Grant A. McArthur Peter MacCallum Cancer Centre
Danny Rischin
Danny Rischin Peter MacCallum Cancer Centre
John F. Seymour
John F. Seymour Peter MacCallum Cancer Centre
Terence J. O'Brien
Terence J. O'Brien Monash University
Declan G. Murphy
Declan G. Murphy King's College London
Benjamin Solomon
Benjamin Solomon Peter MacCallum Cancer Centre
Andrew M. Scott
Andrew M. Scott La Trobe University
Markus Schwaiger
Markus Schwaiger Technical University of Munich

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Pursuing a medical career in the USA doesn’t always require a traditional medical school path. Many students opt for online nursing degrees and accelerated healthcare programs that offer more flexibility and affordability. For registered nurses looking to advance, there are flexible rn to bsn online programs without clinicals which allow you to earn your degree fully online, making it easier to balance work and family commitments.

If you wish to reach the highest levels of clinical practice, 1 year dnp program online options can help you achieve a Doctor of Nursing Practice degree in less time than traditional programs. Budget-conscious students may also want to check out the cheapest dnp programs to reduce tuition costs without sacrificing the quality of their education.

For those looking to start their healthcare journey quickly, lpn online programs provide fast-track learning paths to become a Licensed Practical Nurse. Exploring these diverse online degrees can open many doors to rewarding and well-paying medical careers in the US.

Best Scientists Citing Rodney J. Hicks

Trending Scientists

Recently Published Articles